Vaccine:

Covid-19 vaccine - Vidprevtyn VAT00002, VAT00008

Return to company overview

Sanofi Vaccine Summary Scorecard
*Although the Covid-19 vaccine is the product of a collaboration between Sanofi & GSK, Sanofi is the company that is scored here. GSK is scored on another product, Sotrovimab. 

A: Commitments and AccountabilityScoreC: International cooperationScore
A1 The company publishes a global access plan for its productC1 The company commits to C-TAP or MPP
A2 The company commits to comply with human rights standards in relation to product development and marketing C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator
C4 The company agrees to license its Covid-19 medical products to other companies
E: Equality, non-discrimination & equityScoreT: TransparencyScore
E1 The company makes the active ingredient available on reasonable ground. [Only for therapeutics]T1 The company publishes its R&D costs.
E2 The company commits to full technology transfer to other manufacturersT2 The company publishes its profit margin.
E3 The company commits to non-profit, ‘fair’, or differential pricingT3 The company publishes the average and/or marginal costs of production.
E4 The company equitably distributes supplies globally. [Only applies to vaccines]T4 The company publishes its production capacity.
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]T5 The company publishes the public subsidies it received during product development and/or testing.
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable].T6 The company publishes the text of licensing agreements.
T7 The company registers its clinical trials in public repositories.

Sanofi Vaccine Detailed Evaluation

Explore the results of PAF’s research into Sanofi’s behaviour. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading). 

A: Commitments and Accountability

Overall score:

A1 The company publishes a global access plan for its product

  • Sanofi signed Gates Foundation ‘Commitments to Expanded Access for Covid-19 Diagnostics, Therapeutics and Vaccines’

  • Statement on Covid-19: “We also keep our commitment to making a strong contribution to current global public health priorities by supporting manufacturing and supply of half a billion doses of three different currently approved vaccines: BioNTech’s approved COVID-19 vaccine, co-developed with Pfizer, the vaccine developed by Johnson & Johnson, and the vaccine developed by Moderna. We are working across multiple countries and in coordination with partner manufacturing sites to make vaccines at the extremely large scales required by the pandemic. The manufacturing process is a complex, never-ending job, but our aim is to supply vaccines to as many people as possible.” 

  • Score:

A2 The company commits to comply with human rights standards in relation to product development and marketing

  • Committed to the UNGPs since 2015, and commits to exercise due diligence to respect the fundamental rights of workers 

  • CSR statement on ‘human rights in our activities’ with examples of good practices: ensuring affordable drugs and providing access to healthcare 

  • Score:

C: International Cooperation

Overall score:

C1 The company commits to C-TAP or MPP
  • No commitment to C-TAP or MPP
  • Score: 
C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents
  • No commitment not to enforce patents
  • Score: 
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator
  • Yes, APA for 200M doses on 28/10/2020 (still not approved)
  • Score:
C4 The company agrees to license its Covid-19 medical products to other companies
  • No licensing agreements as of yet.
  • Score:

E: Equality, non-discrimination & equity

Overall score:

E1 The company makes the active ingredient available on reasonable ground
[Only relevant for therapeutics]
E2 The company commits to full technology transfer to other manufacturers
  • No – see C4.
  • Score: 
E3 The company commits to non-profit or ‘fair’ pricing
E4 The company equitably distributes supplies globally. [Only applies to vaccines]
  • So far, signed APAs with the USA, EU and COVAX: 600M doses total; 400M for HICs = 66.6% of vaccines for HICs
  • Also, CEO of Sanofi said they would give the US priority on any future Covid-19 vaccine because they offered more money to fund research (then backpedalled)
  • Score: 
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]
  • No information.
  • Score: 
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable] 
  • No information.
  • Score:

T: Transparency

Overall score:

T1 The company publishes its R&D costs
  • Publishes its R&D expenses for vaccines overall in a press release but not specific to Covid-19 vaccine.
  • Score:
T2 The company publishes its profit margin
  • Not for Vidprevtyn. But published income from all other vaccines / medicines, though not with a profit margin specified.
  • Score:
T3 The company publishes the average and/or marginal costs of production
  • Publishes overall quarterly R&D and sales expenses in financial reports, but not specific to Covid-19 vaccine
  • Score: 
T4 The company publishes its production capacity
  • 600 million doses annually and aimed to double
  • Score:
T5 The company publishes the public subsidies it received during product development and/or testing
  • Yes, funded by BARDA and part of OWS – 2.1B USD.
  • Score:
T6 The company publishes the text of licensing agreements
  • Not licensed to any companies yet
  • Score:
T7 The company registers its clinical trials in public repositories
  • Registers clinical trials plus results in public clinical trial databases
  • Score: